Search

Displaying results 781 - 790 of 4600 in total
  1. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    [L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872] … By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.

  2. Drug

    Ivacaftor

    go.drugbank.com/drugs/DB08820
    ApprovedInvestigational

    It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012. … [L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein

  3. Drug

    Serine

    go.drugbank.com/drugs/DB00133
    ApprovedInvestigationalNutraceutical

    A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.

    Mixtures: Aktiferrin - Saft, PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI)
  4. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous

  5. Drug

    Rabies immune globulin, human

    go.drugbank.com/drugs/DB11603
    Approved

    If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies … Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory

  6. Drug

    Pergolide

    go.drugbank.com/drugs/DB01186
    ApprovedVet approvedWithdrawn

    The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007.

  7. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]

  8. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    It was discovered by phage display technology [A32017]. … The amino acid sequence of two compounds differ by seven amino acids [L1458].

  9. Drug

    Calcium carbimide

    go.drugbank.com/drugs/DB09116
    ApprovedWithdrawn

    Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. … Calcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.

  10. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]